CWP
TXG icon

Concord Wealth Partners’s 10x Genomics TXG Stock Holding History

Concord Wealth Partners’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10
Closed -$558 – 1073
2023
Q2 		$558 Hold
10
– – ﹤0.01% 985
2023
Q1 		$558 Hold
10
– – ﹤0.01% 935
2022
Q4 		$364 Buy
+10
New +$327 ﹤0.01% 1176
2022
Q2 		– Sell
-136
Closed -$10K – 1379
2022
Q1 		$10K Buy
+136
New +$11.9K ﹤0.01% 789

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Concord Wealth Partners's TXG Position: Q3 2023 in Review

Concord Wealth Partners sold out of 10x Genomics (TXG) in Q3 2023, closing a stake of 10 shares — an estimated $558 sold.

Concord Wealth Partners first reported a position in TXG in Q1 2022 and held it in 4 quarters. The position peaked at $10K in Q1 2022. 256 funds tracked by Wall St. Rank hold TXG as of Q3 2023.

  • Concord Wealth Partners reported no remaining 10x Genomics position as of Q3 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 10 10x Genomics shares in Q3 2023, an estimated $558.
  • Concord Wealth Partners first reported a position in 10x Genomics in Q1 2022 and held it in 4 quarters.
  • Concord Wealth Partners's 10x Genomics position peaked at $10K in Q1 2022.
  • 256 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2023.

Based on Concord Wealth Partners's 13F filing for Q3 2023, filed 25 Oct 2023.